Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 5, 2026, 9:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 296 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: HBV (Hepatitis B Virus) Clear all
Completed Phase 1 Interventional

Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors

NCT02143401
View directory record Official record
Conditions
Cirrhosis, Hepatitis B Infection, Hepatitis C Infection, Metastatic Malignant Solid Neoplasm, Recurrent Hepatocellular Carcinoma, Recurrent Malignant Solid Neoplasm, Refractory Malignant Neoplasm, Stage IV Hepatocellular Carcinoma AJCC v7, Unresectable Solid Neoplasm
Interventions
Laboratory Biomarker Analysis, Navitoclax, Pharmacological Study, Sorafenib, Sorafenib Tosylate
Other · Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
10
States / cities
Scottsdale, Arizona • Sacramento, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2024 · Synced Oct 5, 2026, 9:32 AM EDT
Completed No phase listed Observational

Withdrawal of Therapy After Long-Term Antiviral Treatment for Chronic Hepatitis B

NCT01581554
View directory record Official record
Conditions
Chronic Hepatitis B e Antigen Positive, Chronic Hepatitis B e Antigen Negative
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 5, 2026, 9:32 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of Tenofovir Disoproxil Fumarate in Adolescents With Chronic Hepatitis B Infection

NCT00734162
View directory record Official record
Conditions
Hepatitis B Virus (HBV)
Interventions
Tenofovir disoproxil fumarate (TDF), Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
12 Years to 17 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
3
States / cities
Oakland, California • Indianapolis, Indiana • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 1, 2016 · Synced Oct 5, 2026, 9:32 AM EDT
Withdrawn Not applicable Interventional

Abatacept vs Placebo in RA Patients With Hepatitis B on Entecavir Background

NCT02053727
View directory record Official record
Conditions
Rheumatoid Arthritis, Chronic Hepatitis B
Interventions
Abatacept, Placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 16, 2020 · Synced Oct 5, 2026, 9:32 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

VaxTeen Hepatitis B Vaccine Booster Study

NCT00144313
View directory record Official record
Conditions
Hepatitis
Interventions
hepatitis B vaccine
Biological
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
13 Years to 16 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Anchorage, Alaska
Source: ClinicalTrials.gov public record
Updated Sep 21, 2007 · Synced Oct 5, 2026, 9:32 AM EDT
Completed Phase 2 Interventional

The Tolerance of HIV-Infected Patients With Herpes Group Virus Infections to Oral Doses of FIAU

NCT00000654
View directory record Official record
Conditions
Herpes Simplex, HIV Infections, Hepatitis B
Interventions
Fialuridine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years to 65 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1993
U.S. locations
4
States / cities
Birmingham, Alabama • San Diego, California • Bethesda, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2012 · Synced Oct 5, 2026, 9:32 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Hepatitis B and Hepatitis C as Risk Factors for Hepatocellular Carcinoma in African and Asian Immigrants

NCT02366286
View directory record Official record
Conditions
Hepatitis B, Hepatitis C, Carcinoma, Hepatocellular
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
892 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2017
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 5, 2026, 9:32 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

The HOPE Study: Characterizing Patients With Hepatitis B and C

NCT02995252
View directory record Official record
Conditions
Hepatitis B， Chronic, Hepatitis C
Interventions
Blood draws, Tenofovir Alafenamide, Knowledge Index Questionnaire, Liver transient elastography (FibroScan), Liver Biopsy
Other · Drug · Procedure
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 99 Years
Enrollment
550 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2034
U.S. locations
2
States / cities
Baltimore, Maryland • Falls Church, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 5, 2026, 9:32 AM EDT
Completed Phase 1 Interventional

A Study of Pegasys Monotherapy in Patients With Chronic Hepatitis B Who Have Participated in Previous Studies

NCT00962975
View directory record Official record
Conditions
Hepatitis B, Chronic
Interventions
peginterferon alfa-2a [Pegasys]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
2
States / cities
Los Angeles, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 8, 2014 · Synced Oct 5, 2026, 9:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Pharmacokinetics of Tenofovir Alafenamide (TAF) in Adults With Normal Hepatic Function and Adults With Severe Hepatic Impairment

NCT02296853
View directory record Official record
Conditions
Hepatitis B Virus
Interventions
TAF
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 9, 2020 · Synced Oct 5, 2026, 9:32 AM EDT
Terminated Phase 2 Interventional Results available

A Study of JNJ-73763989, Pegylated Interferon Alpha-2a and Nucleos(t)Ide Analogs in Participants With Chronic Hepatitis B Virus Infection

NCT05005507
View directory record Official record
Conditions
Hepatitis B, Chronic
Interventions
JNJ-73763989, PegIFN-alpha-2a, Tenofovir disoproxil, TAF, ETV
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Hillsborough, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 6, 2024 · Synced Oct 5, 2026, 9:32 AM EDT
Terminated No phase listed Observational

Tubular Function in Asian-American Patients Receiving TDF or ETV for HBV Treatment

NCT01715987
View directory record Official record
Conditions
Hepatitis B
Interventions
Tenofovir Disoproxil Fumarate, Entecavir
Drug
Lead sponsor
New Discovery LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
2
States / cities
Los Angeles, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 6, 2017 · Synced Oct 5, 2026, 9:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Study of GSK3228836 Pharmacokinetics in Participants With Hepatic Impairment

NCT04971928
View directory record Official record
Conditions
Hepatitis B
Interventions
GSK3228836
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
2
States / cities
Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 27, 2022 · Synced Oct 5, 2026, 9:32 AM EDT
Terminated Phase 2 Interventional Results available

A Study of ABI-H2158-containing Regimens in Participants With Chronic Hepatitis B Virus Infection

NCT04398134
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
ABI-H2158, Placebo, Entecavir (ETV)
Drug
Lead sponsor
Assembly Biosciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
13
States / cities
Los Angeles, California • Pasadena, California • Redwood City, California + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2022 · Synced Oct 5, 2026, 9:32 AM EDT
Active, not recruiting Phase 2 Interventional

VIR-2218 and Peginterferon Alfa-2a for Chronic Hepatitis B

NCT06092333
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
VIR-2218 and peginterferon alfa-2a
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 5, 2026, 9:32 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Adefovir Dipivoxil in Children and Adolescents With Chronic Hepatitis B

NCT00095121
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
Placebo (PLB), Adefovir Dipivoxil (ADV), Lamivudine
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
2 Years to 17 Years
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 22, 2012 · Synced Oct 5, 2026, 9:32 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Healthy Planet Hepatitis B

NCT04503993
View directory record Official record
Conditions
Hepatitis B
Interventions
Hepatitis B surface antigen, Hepatitis B core antibody, and Hepatitis B surface antibody
Other
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 75 Years
Enrollment
5,004 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated May 10, 2022 · Synced Oct 5, 2026, 9:32 AM EDT
Completed No phase listed Observational

Epidemiology, Infectivity and Natural History of Hepatitis C Virus Infection

NCT00004850
View directory record Official record
Conditions
Hepatitis C, Hepatitis B
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
805 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1991
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 5, 2026, 9:32 AM EDT
Terminated Phase 2 Interventional Results available

A Study Evaluating Treatment Intensification With ABI-H0731 in Participants With Chronic Hepatitis B Infection on Nucleos(t)Ide Reverse Transcriptase Inhibitors

NCT04454567
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
ABI-H0731, Placebo, NrtI
Drug
Lead sponsor
Assembly Biosciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
9
States / cities
Los Angeles, California • Pasadena, California • San Diego, California + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2022 · Synced Oct 5, 2026, 9:32 AM EDT
Not listed Phase 2 Interventional

A Safety Study to Evaluate 12 Weeks of Treatment with Clevudine in Patients Infected with Hepatitis B Virus.

NCT00044135
View directory record Official record
Conditions
Hepatitis B
Interventions
clevudine (drug)
Drug
Lead sponsor
Triangle Pharmaceuticals
Industry
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
2
States / cities
Chicago, Illinois • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 5, 2026, 9:32 AM EDT
Terminated No phase listed Observational

An Observational Study of Patients With Chronic Hepatitis B (CHB) Infection

NCT03692897
View directory record Official record
Conditions
Hepatitis B, Hepatitis, Liver Diseases
Interventions
All approved therapies for the treatment of Chronic Hepatitis B (CHB)
Other
Lead sponsor
Target PharmaSolutions, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,708 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
30
States / cities
Phoenix, Arizona • Los Angeles, California • Pasadena, California + 21 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Oct 5, 2026, 9:32 AM EDT
Completed Phase 2Phase 3 Interventional

Study of Adding Entecavir to Current Lamivudine Therapy in HIV and HBV Co-Infected Patients

NCT00051038
View directory record Official record
Conditions
Hepatitis B
Interventions
Entecavir
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
16 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
5
States / cities
New Haven, Connecticut • Altamonte Springs, Florida • Lousiville, Kentucky + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2011 · Synced Oct 5, 2026, 9:32 AM EDT
Completed Not applicable Interventional

Immune System Function Following Vaccination in HIV Infected Children Taking Anti-HIV Drugs

NCT00257127
View directory record Official record
Conditions
HIV Infections
Interventions
Pneumococcal 7-valent conjugate vaccine, Pneumococcal polysaccharide vaccine, Hepatitis B vaccine, Measles, mumps, and rubella virus vaccine, live
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Years to 23 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
24
States / cities
Birmingham, Alabama • Alhambra, California • Long Beach, California + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 5, 2026, 9:32 AM EDT
Recruiting Phase 2 Interventional

Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States

NCT05832229
View directory record Official record
Conditions
Cirrhosis, Cirrhosis, Liver, Cirrhosis Early, Cirrhosis Due to Hepatitis B, Cirrhosis Advanced, Cirrhosis Infectious, Cirrhosis Alcoholic, Cirrhosis Due to Hepatitis C
Interventions
Rosuvastatin
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 75 Years
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
13
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 5, 2026, 9:32 AM EDT